October 31, 2024

Novel NKG2D-targeting bispecific antibodies improve B celllymphoma killing

Novel NKG2D-targeting bispecific antibodies improve B celllymphoma killing

Combination approach could potentiate the success of immunotherapy

MEDICAL NEED: Owing to advances in cancer research, mortality rates have decreased in recent years.1
However, there are many patients who do not benefit from the plethora of available therapies because
tumors develop diverse immune escape mechanisms. Therefore, further development, investigation and
improvement of current and new therapies is imperative.

Therapeutic monoclonal antibodies (mAb) are a cornerstone of immunotherapy with recruitment and stimulation of effector cells as a prominent goal. As a versatile tool, they are used as naked antibody, in antibody-drug conjugates to deliver toxic agents, as multi-specific constructs to simultaneously target different epitopes, as antibody-cytokine fusion proteins to induce cytokine production, and many more.2 However, this process is hindered in some patients.

Strategies to improve effector cell engagement include Fc-engineering, combination of different mAb or the development of further bispecific antibodies (bsAbs) – all aimed at improving antibody binding to specific immune cell receptors, thereby triggering a particular signaling pathway that either inhibits or stimulates the cell.

Targeting NKG2D to improve immunosurveillance

Among various immune cell populations, the receptors of natural killer (NK) cells and T lymphocytes (T cells) are important targets, as these cell types are one of the key players in tumor elimination. One of the stimulatory receptors that plays an important role in immunosurveillance of tumors and pathogens, is the activating receptor natural killer group 2 member D (NKG2D), which is expressed by NK cells, T cells and other immune cells.3 NKG2D or its ligand have been investigated as antibody-targets in cancer cell killing studies4–6 and the effect of NKG2D-immunotherapies in cancer patients has been evaluated in clinical trials with autologous T or NK cells bearing NKG2D chimeric antigen receptor (CAR).7

In a collaborative approach of the Universities of Kiel, Munich, and Braunschweig with YUMAB GmbH, novel NKG2D-specific antibodies have been developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells (GRANTA-519).8 Using phage display technology, a set of NKG2D-specific antibodies (scFv) was discovered and the most potent candidates were fused to an antigen-binding fragment (Fab) derived from the CD20-specific monoclonal antibody rituximab to generate a bsAb [CD20xNKG2D].

Lutz and coworkers demonstrated an in vitro activation of NK cells with this novel bsAb. Furthermore, the combination of [CD20xNKG2D] with the therapeutic antibody anti-CD38 (Daratumumab) or an Fc-engineered anti-CD19 antibody enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells, as shown in vitro in CD38+/CD20+ or CD19+/CD20+ expressing GRANTA-519 cells (Figure 1. A-B).

Figure 1. Cytotoxic activity of mononuclear cells (MNC) incubated with [CD20xNKG2D] and (A) anti-CD38 (Daratumumab) or (B) Fc-engineered anti-CD19 antibody on GRANTA-519 cells (adapted from reference 8).
Figure 2. Cytotoxic activity of CD8+ αβ T cells, treated with [CD20xNKG2D] alone or in combination with [CD19xCD3], on GRANTA-519 cells (adapted from reference 8).

The combination of [CD20xNKG2D] and a T cell engager bsAB [CD19xCD3] in a dual-dual approach significantly increased CD8+ (αβ T cell receptor) T cell-mediated lysis of GRANTA-519 cells (Figure 2.).

CONCLUSION

Lutz and colleagues demonstrated that bispecific antibodies can enhance the efficacy of immunotherapy by including mAb or NK/T cell engager molecules in a combinatory approach.

The immune potential of the novel bispecific antibody needs be tested in animal models as a next step towards clinical development of a new cancer immunotherapy.

Original News

Our latest News

discover more
TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]

Novel analysis of intrinsically disordered proteins

Novel analysis of intrinsically disordered proteins

Researchers from Mainz University and EMBL Hamburg present a new approach for structurally characterising disordered proteins by combining two different analysis methods. Proteins are the molecules that perform most ‘actions’ in the cell, and thus, are key for our body functions. Essentially, proteins are strings of amino acids, which, in most cases, fold like origami […]

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Researchers at the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have investigated the association between an individual’s risk of colorectal cancer and repeated diagnoses of colorectal polyp in relatives. They conclude that, in particular, the risk of developing colorectal cancer at a young age is significantly increased […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp